Exploring the contribution of estrogen to amyloid-beta regulation: A novel multifactorial computational modeling approach

Frontiers in Pharmacology

Volumn 4 MAR, Issue , 2013, Pages

  Anastasio, Thomas J ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Alzheimer disease; Amyloid ; Computational model; Declarative programming; Estrogen; Formal methods; Multi drug therapy; Multifactorial process

Indexed keywords

AMYLOID BETA PROTEIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA AGONIST; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA AGONIST; HORMONE RECEPTOR STIMULATING AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ARTICLE; ESTROGEN ACTIVITY; EXPLORATORY RESEARCH; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; PREDICTION; PREDICTIVE VALUE; PROTEIN INTERACTION; REGULATORY MECHANISM; SIMULATION;

EID: 84877965452     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00016     Document Type: Article

References (94)

1. Abuznait, A. H., Cain, C., Ingram, D., Burk, D., and Kaddoumi, A. (2011). Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease. J. Pharm. Pharmacol. 63, 1111-1118.
2. Allinson, T. M., Parkin, E. T., Turner, A. J., and Hooper, N. M. (2003). ADAMs family members as amyloid precursor protein alpha-secretases. J. Neurosci. Res. 74, 342-352.
3. Alzamora, R., Brown, L. R., and Harvey, B. J. (2007). Direct binding and activation of protein kinase C isoforms by aldosterone and 17beta-estradiol. Mol. Endocrinol. 21, 2637-2650.
4. Anastasio, T. J. (2011). Data-driven modeling of Alzheimer disease pathogenesis. J. Theor. Biol. 290, 60-72.
5. Anderson, G. L., Limacher, M., Assaf, A. R., Bassford, T., Beresford, S. A., Black, H., et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712.
6. Bajda, M., Guzior, N., Ignasik, M., and Malawska, B. (2011). Multi-target-directed ligands in Alzheimer's disease treatment. Curr. Med. Chem. 18, 4949-4975.
7. Barlow, D. H. (2008). The medical management of menopause: to treat or not to treat? Ann. N. Y. Acad. Sci. 1127, 134-139.
8. Benvenuti, S., Luciani, P., Vannelli, G. B., Gelmini, S., Franceschi, E., Serio, M., et al. (2005). Estrogen and selective estrogen receptor modulators exert neuroprotective effects and stimulate the expression of selective Alzheimer's disease indicator-1, a recently discovered antiapoptotic gene, in human neuroblast long-term cell cultures. J. Clin. Endocrinol. Metab. 90, 1775-1782.
9. Bodles, A. M., and Barger, S. W. (2005). Secreted beta-amyloid precursor protein activates microglia via JNK and p38-MAPK. Neurobiol. Aging 26, 9-16.
10. Borchelt, D. R., Thinakaran, G., Eckman, C. B., Lee, M. K., Davenport, F., Ratovitsky, T., et al. (1996). Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17, 1005-1013.
11. Bulgarelli, I., Tamiazzo, L., Bresciani, E., Rapetti, D., Caporali, S., Lattuada, D., et al. (2009). Desacyl-ghrelin and synthetic GH-secretagogus modulate the production of inflammatory cyotkines in mouse microglia cells stimulated by beta-amyloid fibrils. J. Neurosci. Res. 87, 2718-2727.
12. Carroll, J. C., Rosario, E. R., Chang, L., Stanczyk, F. Z., Oddo, S., Laferla, F. M., et al. (2007). Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J. Neurosci. 27, 13357-13365.
13. Cheng, X., McAsey, M. E., Li, M., Randall, S., Cady, C., Nathan, B. P., et al. (2007). Estradiol replacement increases the low-density lipoprotein receptor related protein (LRP) in the mouse brain. Neurosci. Lett. 417, 50-54.
14. Cirrito, J. R., Deane, R., Fagan, A. M., Spinner, M. L., Parsadanian, M., Finn, M. B., et al. (2005). P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115, 3285-3290.
15. Cisse, M., Braun, U., Leitges, M., Fisher, A., Pages, G., Checler, F., et al. (2011). ERK1-independent alpha-secretase cut of beta-amyloid precursor protein via M1 muscarinic receptors and PKCalpha/epsilon. Mol. Cell. Neurosci. 47, 223-232.
16. Clavel, M., Durán, R., Eker, S., Lincoln, P., Martí-Oliet, N., Meseguer, J., et al. (2007). All About Maude - A High-Preformance Logical Framework: How to Specify, Program, and Verify Systems in Rewriting Logic. Berlin: Springer.
17. Daniel, J. M. (2012). Estrogens, estrogen receptors, and female cognitive aging: the impact of timing. Horm. Behav. 63, 231-237.
18. Dave, J. R., Williams, A. J., Moffett, J. R., Koenig, M. L., and Tortella, F. C. (2003). Studies on neuronal apoptosis in primary forebrain cultures: neuroprotective/anti-apoptotic action of NR2B NMDA antagonists. Neurotox. Res. 5, 255-264.
19. de la Torre, J. C. (2009). Cerebrovascular and cardiovascular pathology in Alzheimer's disease. Int. Rev. Neurobiol. 84, 35-48.
20. De Strooper, B. (2003). Aph-1, Pen-2, and Nicastrin with Presenilin generate an active gamma-Secretase complex. Neuron 38, 9-12.
21. De Strooper, B., Vassar, R., and Golde, T. (2010). The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat. Rev. Neurol. 6, 99-107.
22. Deane, R., Du Yan, S., Submamaryan, R. K., Larue, B., Jovanovic, S., Hogg, E., et al. (2003). RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9, 907-913.
23. Deane, R., Wu, Z., Sagare, A., Davis, J., Du Yan, S., Hamm, K., et al. (2004). LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344.
24. Di Carlo, M. (2010). Beta amyloid peptide: from different aggregation forms to the activation of different biochemical pathways. Eur. Biophys. J. 39, 877-888.
25. Eker, S., Knapp, M., Laderoute, K., Lincoln, P., Meseguer, J., and Sonmez, K. (2002). Pathway logic: symbolic analysis of biological signaling. Pac. Symp. Biocomput. 400-412.
26. Esch, F. S., Keim, P. S., Beattie, E. C., Blacher, R. W., Culwell, A. R., Oltersdorf, T., et al. (1990). Cleavage of amyloid beta peptide during constitutive processing of its precursor. Science 248, 1122-1124.
27. Espeland, M. A., Rapp, S. R., Shumaker, S. A., Brunner, R., Manson, J. E., Sherwin, B. B., et al. (2004). Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 291, 2959-2968.
28. Estaquier, J., Vallette, F., Vayssiere, J. L., and Mignotte, B. (2012). The mitochondrial pathways of apoptosis. Adv. Exp. Med. Biol. 942, 157-183.
29. Faghihi, M. A., Modarresi, F., Khalil, A. M., Wood, D. E., Sahagan, B. G., Morgan, T. E., et al. (2008). Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat. Med. 14, 723-730.
30. Fisher, J., and Henzinger, T. A. (2007). Executable cell biology. Nat. Biotechnol. 25, 1239-1249.
31. Guglielmotto, M., Aragno, M., Autelli, R., Gilliberto, L., Novo, E., Collombatto, S., et al. (2009). The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J. Neurochem. 108, 1045-1056.
32. Hardy, J., and Selkoe, D. J. (2002). The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356.
33. He, W., Lu, Y., Qahwash, I., Hu, X.-Y., Chang, A., and Yan, R. (2004). Reticulon family members modulate BACE1 activity and amyloid-beta peptide generation. Nat. Med. 10, 959-965.
34. Heneka, M. T., Kummer, M. P., Weggen, S., Bulic, B., Multhaup, G., Munter, L., et al. (2011). Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. Curr. Alzheimer Res. 8, 115-131.
35. Hiltunen, M., Mäkinen, P., Peräniemi, S., Sivenius, J., Van Groen, T., Soininen, H., et al. (2009). Focal cerebral ischemia in rats alters APP processing and expression of Abeta peptide degrading enzymes in the thalamus. Neurobiol. Dis. 35, 103-113.
36. Hlavacek, W. S., Faeder, J. R., Blinov, M. L., Posner, R. G., Hucka, M., and Fontana, W. (2006). Rules for modeling signal-transduction systems. Sci. STKE 2006, re6.
37. Hu, J., Igarashi, A., Kamata, M., and Nakagawa, H. (2001). Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J. Biol. Chem. 276, 47863-47868.
38. Huth, M., and Ryan, M. (2004). Logic in Computer Science: Modelling and Reasoning about Systems. Cambridge: Cambridge University Press.
39. Jellinger, K. A. (2003). General aspects of neurodegeneration. J. Neural Transm. Suppl. 101-144.
40. Kanekiyo, T., and Bu, G. (2009). Receptor-associated protein interacts with amyloid-beta peptide and promotes its cellular uptake. J. Biol. Chem. 284, 33352-33359.
41. Kanemitsu, H., Tomiyama, T., and Mori, H. (2003). Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci. Lett. 350, 113-116.
42. Kim, S. K., Park, H. J., Hong, H. S., Baik, E. J., Jung, M. W., and Mook-Jung, I. (2006). ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. FASEB J. 20, 157-159.
43. Kuhnke, D., Jedlitschky, G., Grube, M., Krohn, M., Jucker, M., Mosyagin, I., et al. (2007). MDR1-P-glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol. 17, 347-353.
44. Kume, H., Konishi, Y., Murayama, K. S., Kametani, F., and Araki, W. (2009). Expression of reticulon 3 in Alzheimer's disease brain. Neuropathol. Appl. Neurobiol. 35, 178-188.
45. Lakshmana, M. K., Chen, E., Yoon, I.-S., and Kang, D. E. (2008). C-terminal 37 residues of LRP promote the amyloidogenic processing of APP independent of FE65. J. Cell. Mol. Med. 12, 2665-2674.
46. Leon, R., and Marco-Contelles, J. (2011). A step further towards multitarget drugs for Alzheimer and neuronal vascular diseases: targeting the cholinergic system, amyloid-beta aggregation and Ca(2+) dyshomeostasis. Curr. Med. Chem. 18, 552-576.
47. Levin-Allerhand, J., McEwen, B. S., Lominska, C. E., Lubahn, D. B., Korach, K. S., and Smith, J. D. (2001). Brain region-specific up-regulation of mouse apolipoprotein E by pharmacological estrogen treatments. J. Neurochem. 79, 796-803.
48. Levin-Allerhand, J. A., Lominska, C. E., Wang, J., and Smith, J. D. (2002). 17Alpha-estradiol and 17beta-estradiol treatments are effective in lowering cerebral amyloid-beta levels in AbetaPPSWE transgenic mice. J. Alzheimers Dis. 4, 449-457.
49. Liang, K., Yang, L., Yin, C., Xiao, Z., Zhang, J., Liu, Y., et al. (2010). Estrogen stimulates degradation of beta-amyloid peptide by up-regulating neprilysin. J. Biol. Chem. 285, 935-942.
50. Luciani, P., Deledda, C., Rosati, F., Benvenuti, S., Cellai, I., Dichiara, F., et al. (2008). Seladin-1 is a fundamental mediator of the neuroprotective effects of estrogen in human neuroblast long-term cell cultures. Endocrinology 149, 4256-4266.
51. Manelli, A. M., Stine, W. B., Van Eldik, L. J., and Ladu, M. J. (2004). ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. J. Mol. Neurosci. 23, 235-246.
52. Marjoribanks, J., Farquhar, C., Roberts, H., and Lethaby, A. (2012). Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev. 7, CD004143.
53. Moyer, V. A., and On Behalf of the U.S. Preventive Services Task Force. (2012). Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. preventive services task force recommendation statement. Ann. Intern. Med. doi:10.7326/0003-4819-158-1-201301010-00553. [Epub ahead of print].
54. Muhammad, A., Flores, I., Zhang, H., Yu, R., Staniszewski, A., Planel, E., et al. (2008). Retromer deficiency observed in Alzheimer's disease causes hippocampal dysfunction, neurodegeneration, and Abeta accumulation. Proc. Natl. Acad. Sci. U.S.A. 105, 7327-7332.
55. Nelson, H. D., Walker, M., Zakher, B., and Mitchell, J. (2012). Menopausal hormone therapy for the primary prevention of chronic conditions: a systematic review to update the U.S. Preventive Services Task Force recommendations. Ann. Intern. Med. 157, 104-113.
56. North American Menopause, S. (2012). The 2012 hormone therapy position statement of: the North American Menopause Society. Menopause 19, 257-271.
57. O'Connor, T., Sadleir, K. R., Maus, E., Velliquette, R. A., Zhou, J., Cole, S. L., et al. (2008). Phosphorylation of the translation initiation factor e1F2alpha increases BACE1 levels and promotes amyloidogenesis. Neuron 60, 988-1009.
58. Oda, S., Oda, T., Takabuchi, S., Nishi, K., Wakamatsu, T., Tanaka, T., et al. (2009). The calcium channel blocker cilnidipine selectively suppresses hypoxia-inducible factor 1 activity in vascular cells. Eur. J. Pharmacol. 606, 130-136.
59. Pike, C. J. (1999). Estrogen modulates neuronal Bcl-xL expression and beta-amyloid-induced apoptosis: relevance to Alzheimer's disease. J. Neurochem. 72, 1552-1563.
60. Rao, A. K., Dietrich, A. K., Ziegler, Y. S., and Nardulli, A. M. (2011). 17beta-Estradiol-mediated increase in Cu/Zn superoxide dismutase expression in the brain: a mechanism to protect neurons from ischemia. J. Steroid Biochem. Mol. Biol. 127, 382-389.
61. Sarajärvi, T., Haapasalo, A., Viswanathan, J., Mäkinen, P., Laitinen, M., Soininen, H., et al. (2009). Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis. J. Biol. Chem. 284, 34433-34443.
62. Sastre, M., Dewachter, I., Rossner, S., Bogdanovic, N., Rosen, E., Borghgraef, P., et al. (2006). Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. U.S.A. 103, 443-448.
63. Saunders, A. M. (2000). Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses. J. Neuropathol. Exp. Neurol. 59, 751-758.
64. Scheibel, A. B., Duong, T. H., and Jacobs, R. (1989). Alzheimer's disease as a capillary dementia. Ann. Med. 21, 103-107.
65. Scholefield, Z., Yates, E. A., Wayne, G., Amour, A., McDowell, W., and Turnbull, J. E. (2003). Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's Beta-secretase. J. Cell Biol. 163, 97-107.
66. Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., et al. (2000). Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106, 1489-1499.
67. Shifren, J. L., and Schiff, I. (2010). Role of hormone therapy in the management of menopause. Obstet. Gynecol. 115, 839-855.
68. Shughrue, P. J., and Merchenthaler, I. (2000). Estrogen is more than just a "sex hormone": novel sites for estrogen action in the hippocampus and cerebral cortex. Front. Neuroendocrinol. 21, 95-101.
69. Sisodia, S. S. (1992). Beta-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. U.S.A. 89, 6075-6079.
70. Small, S. A. (2008). Retromer sorting: a pathogenic pathway in late-onset Alzheimer disease. Arch. Neurol. 65, 323-328.
71. Srivastava, R. A., Bhasin, N., and Srivastava, N. (1996). Apolipoprotein E gene expression in various tissues of mouse and regulation by estrogen. Biochem. Mol. Biol. Int. 38, 91-101.
72. Stone, D. J., Rozovsky, I., Morgan, T. E., Anderson, C. P., Hajian, H., and Finch, C. E. (1997). Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp. Neurol. 143, 313-318.
73. Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., et al. (1993). Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 90, 8098-8102.
74. Sudoh, S., Frosch, M. P., and Wolf, B. A. (2002). Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and insoluble pools in CHO-695 cells. Biochemistry 41, 1090-1099.
75. Talcott, C. (2008). "Pathway logic," in Lecture Notes in Computer Science, eds. M. Bernardo, P. Degano, and G. Zavattaro (Berlin: Springer), 21-53.
76. Tamagno, E., Guglielmotto, M., Aragno, M., Borghi, R., Autelli, R., Giliberto, L., et al. (2008). Oxidative stress activates a positive feedback between the gamma and beta secretase cleavages of the beta-amyloid precursor protein. J. Neurochem. 104, 683-695.
77. Tamagno, E., Guglielmotto, M., Giliberto, L., Vitali, A., Borghi, R., Autelli, R., et al. (2009). JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiol. Aging 30, 1563-1573.
78. Tesco, G., Ho Koh, Y., Kang, E., Cameron, A., Das, S., Sena-Esteves, M., et al. (2007). Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron 54, 721-737.
79. Udan, M. L. D., Ajit, D., Crouse, N. R., and Nichols, M. R. (2008). Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J. Neurochem. 104, 524-533.
80. Ulery, P. G., Beers, J., Mikhailenko, I., Tanzi, R. E., Rebeck, G. W., Hyman, B. T., et al. (2000). Modulation of beta-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. J. Biol. Chem. 275, 7410-7415.
81. Valles, S. L., Dolz-Gaiton, P., Gambini, J., Borras, C., Lloret, A., Pallardo, F. V., et al. (2010). Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPAR gamma expression in cultured astrocytes. Brain Res. 1312, 138-144.
82. Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., et al. (1999). Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
83. Vassar, R., Kovacs, D. M., Yan, R., and Wong, P. C. (2009). The beta-secretase enzyme BACE in health and Alzheimer's disease: regulation, cell biology, function, and therapeutic potential. J. Neurosci. 29, 12787-12794.
84. Vingtdeux, V., and Marambaud, P. (2012). Identification and biology of alpha-secretase. J. Neurochem. 120(Suppl. 1), 34-45.
85. Walsh, D. M., and Selkoe, D. J. (2007). A beta oligomers - a decade of discovery. J. Neurochem. 101, 1172-1184.
86. Wang, J. M., Irwin, R. W., and Brinton, R. D. (2006). Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 103, 16983-16988.
87. Wang, W.-X., Rajeev, B. W., Stromberg, A. J., Ren, N., Tang, G., Huang, Q., et al. (2008). The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J. Neurosci. 28, 1213-1223.
88. Wilson-Annan, J., O'Reilly, L. A., Crawford, S. A., Hausmann, G., Beaumont, J. G., Parma, L. P., et al. (2003). Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. J. Cell Biol. 162, 877-887.
89. Yao, M., Nguyen, T. V., and Pike, C. J. (2005). Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. J. Neurosci. 25, 1149-1158.
90. Yao, M., Nguyen, T. V., and Pike, C. J. (2007). Estrogen regulates Bcl-w and Bim expression: role in protection against beta-amyloid peptide-induced neuronal death. J. Neurosci. 27, 1422-1433.
91. Yin, K. J., Lee, J. M., Chen, S. D., Xu, J., and Hsu, C. Y. (2002). Amyloid-beta induces Smac release via AP-1/Bim activation in cerebral endothelial cells. J. Neurosci. 22, 9764-9770.
92. Yoon, I.-S., Chen, E., Busse, T., Repetto, E., Lakshmana, M. K., Koo, E. H., et al. (2007). Low-density lipoprotein receptor-related protein promotes amyloid precursor protein trafficking to lipid rafts in the endocytic pathway. FASEB J. 21, 2742-2752.
93. Youle, R. J., and Strasser, A. (2008). The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47-59.
94. Zhang, X., Zhou, K., Wang, R., Cui, J., Lipton, S. A., Liao, F.-F., et al. (2007). Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J. Biol. Chem. 282, 10873-10880.